www.tfda.or.t 1 Examples of subregional collaboration: the experience of Operation Mamba I & II in East African Community (EAC) The case of TANZANIA IMPACT Regional Conference, 9-10 Nov 2009 Kempton Park, RSA Director, Medicines and Cosmetics Tanzania Food and Drugs Authority
16
Embed
Www.tfda.or.tz 1 Examples of subregional collaboration: the experience of Operation Mamba I & II in East African Community (EAC) The case of TANZANIA IMPACT.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
www.tfda.or.tz1
Examples of subregional collaboration: the experience of Operation Mamba I & II in East African Community (EAC)
The case of TANZANIA
IMPACT Regional Conference, 9-10 Nov 2009Kempton Park, RSA
Director, Medicines and CosmeticsTanzania Food and Drugs Authority
www.tfda.or.tz2
OUTLINE OF THE PRESENTATION
1. Background
2. Objectives
3. Findings– Operation Mamba I, 2008– Operation Mamba II, 2009
4. Lessons learned
5. Recommendations
www.tfda.or.tz3
33
www.tfda.or.tz4
Background• September 2007
– Joint taskforce between the Tanzania Food and Drugs Authority (TFDA) and the Tanzania Police• Joint operations to identify and confiscate counterfeit products
• July 2008– INTERPOL/IMPACT expressed interest to collaborate with Tanzania
& Uganda in combating counterfeit medicines– Tanzania Taskforce was expanded, headed by the TFDA and the
• Public awareness on the dangers of counterfeit medicines raised
• Counterfeit medicines cross borders• Metakelfin in Tanzania and Uganda
• Challenge• Identifying source of counterfeit medicines
• Need to carry out one operation in the region annually
www.tfda.or.tz
Final Meeting: Kampala
13
www.tfda.or.tz
• WHO/IMPACT is requested to continue providing both technical and financial support to national authorities to conduct at least one operation annually
• Need to conduct operational research to determine extent of counterfeit problem in the region
– Recommended during IMPACT General Meeting in Lisbon, 2007
• Capacity building of national law enforcers and drug testing laboratories on identification of counterfeit medical products